| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Artelo Biosciences GAAP EPS of $4.00 | 2 | Seeking Alpha | ||
| 14.05. | ARTELO BIOSCIENCES, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 28.04. | Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development | 3 | GlobeNewswire (USA) | ||
| 20.04. | Artelo Biosciences Stock Gains 16% On Positive Pain Research Publication | 1 | RTTNews | ||
| 20.04. | Artelo veröffentlicht Forschungsdaten zu FABP5-Inhibitor ART26.12 als Schmerztherapie | 5 | Investing.com Deutsch | ||
| 20.04. | Artelo publishes pain research on FABP5 inhibitor ART26.12 | 1 | Investing.com | ||
| ARTELO BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.04. | Artelo Biosciences: Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile | 2 | GlobeNewswire (USA) | ||
| 07.04. | ARTELO BIOSCIENCES, INC. - S-1, General form for registration of securities | - | SEC Filings | ||
| 07.04. | Artelo Biosciences erfüllt wieder NASDAQ-Börsenanforderungen | 2 | Investing.com Deutsch | ||
| 07.04. | Artelo Biosciences regains Nasdaq listing compliance | 1 | Investing.com | ||
| 07.04. | Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements | 138 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop... ► Artikel lesen | |
| 07.04. | ARTELO BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | Artelo Biosciences closes $11M private placement | 1 | Investing.com | ||
| 30.03. | Artelo Biosciences sichert sich 11 Mio. US-Dollar durch Privatplatzierung | 3 | Investing.com Deutsch | ||
| 30.03. | Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
| 27.03. | Privatplatzierung: Artelo Biosciences sichert sich 11 Millionen US-Dollar | 10 | Investing.com Deutsch | ||
| 27.03. | Artelo Biosciences raises $11 million in private placement | 1 | Investing.com | ||
| 27.03. | Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules | 300 | GlobeNewswire (Europe) | SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate... ► Artikel lesen | |
| 27.03. | Morning Market Movers: Artelo Biosciences, Onconetix, Datacentrex, Robin Energy See Big Swings | 695 | AFX News | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 26.03. | ARTELO BIOSCIENCES, INC. - 8-K, Current Report | 4 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,30 | +0,77 % | Tagesvorschau 15. Mai: Biontech-HV, BVB-Quartal, US-Industriedaten - das bringt der Freitag | Die turbulente Bilanzwoche klingt aus - doch der Freitag hält für Anleger noch einige spannende Termine bereit.Zum Wochenausklang dünnt der Terminkalender zwar aus, gewinnt aber spürbar an Schärfe.... ► Artikel lesen | |
| BB BIOTECH | 47,800 | -0,31 % | Aktien KW 17 Märkte im Würgegriff. Planloser Trump , selbstbewusterer Iran. Lösungen müssen her. News. Rheinmetall. ITM Power. Porsche. The Platform Group. K+S. Bugatti. Circus. Surteco. NanoRepro. BB Biotech. Mensch und Maschine. ATOSS. MHP Hotel | Aktien - letzte Woche warteten die Märkte auf eine Lösung des Iran-Kriegs. Aber die Iraner sehen sich im Vorteil und Trump verlängert "auf unbestimmte Zeit" den Waffenstillstand. Aber die Strasse von... ► Artikel lesen | |
| QIAGEN | 30,095 | +0,62 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| MODERNA | 40,770 | -1,50 % | Moderna to face FDA AdCom review for flu shot | ||
| AMGEN | 290,00 | +1,68 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| NOVAVAX | 7,760 | -2,63 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| STRYKER | 270,00 | -2,35 % | Stryker Buys Amplitude Vascular Systems For Upto $835 Mln To Expand Vascular Treatment Business | WASHINGTON (dpa-AFX) - Tuesday, BioStar Capital announced that Amplitude Vascular Systems, Inc., a medical technology company, has been acquired by Stryker Corporation (SYK) at a purchase price... ► Artikel lesen | |
| BIOGEN | 162,88 | +0,80 % | Biogen Inc.: Biogen Completes Acquisition of Apellis Pharmaceuticals | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis... ► Artikel lesen | |
| ILLUMINA | 123,84 | +1,46 % | RBC Capital assumes Illumina stock coverage with outperform rating | ||
| CRISPR THERAPEUTICS | 42,910 | +2,75 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 14,380 | -1,17 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| AAP IMPLANTATE | 2,000 | -0,99 % | EQS-HV: aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: aap Implantate AG
/ Bekanntmachung der Einberufung zur Hauptversammlung
aap Implantate AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Berlin... ► Artikel lesen | |
| OCUGEN | 1,184 | +0,85 % | Ocugen schließt Platzierung von Wandelanleihen über 130 Millionen US-Dollar ab | ||
| INOVIO PHARMACEUTICALS | 1,132 | +5,70 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| BIONXT SOLUTIONS | 0,260 | +2,36 % | BioNxt treibt das Semaglutid-ODF-Programm in die aktive pharmazeutische Entwicklung voran | VANCOUVER, BC / ACCESS Newswire /
19. Mai 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives
Biowissenschaftsunternehmen, das sich... ► Artikel lesen |